Fig. 6

ILC2 are significantly increased in prostate cancer. a Quantification of PGD2 in supernatants of different human cancer cell lines (n = 2). b Representative example of flow cytometry analysis of expression of B7H6 in prostate cancer cell lines DU145 and PC3, or in a control cell line (721.221). c Relative frequencies of the ILC2 subset among total ILCs in healthy donors (HD) and prostate cancer patients (Prostate) (n = 21). d Relative frequencies of NKp30 expressing ILC2 in peripheral blood of HD and Prostate (n = 21). e Frequency of M-MDSC in peripheral blood of HD and Prostate (n = 21). f Relative frequencies of the ILC2 subset among total ILCs in healthy donors (HD, n = 21) and prostate cancer patients at stage (Gleason score) 6 (n = 8), 7 (n = 8), or 9/10 (n = 5) or in patients with benign prostate hypertrophy (BPH, n = 5). g Representative examples of flow cytometry analysis of innate lymphoid cell subsets in blood of FVB female mice (blood CTR, n = 5) and in blood (n = 29), spleen (n = 29) and prostate (n = 19) of TRAMP mice. h Relative frequencies of the ILC2 subset among total ILCs in blood of FVB female mice (blood CTR) and in blood, spleen and prostate of TRAMP mice. i Correlation of ILC2 and M-MDSCs in prostate tumours of TRAMP mice (n = 19) (three independent experiments). Error bars are s.e.m. Statistical analysis was performed using t test (c–e, h) and Kruskal-Wallis test (f)